Magle Chemoswed Holding AB (52X)

Overview

Magle Chemoswed Holding AB (publ), along with its subsidiaries, is a notable entity in Sweden's pharmaceutical and medical device sector, functioning as a contract development and manufacturing organization (CDMO). The company dedicates its expertise to supporting the pharmaceutical and medical device industries through contract-based engagements. Founded in 1944 and headquartered in Malmö, Sweden, Magle Chemoswed has established itself as a pivotal player in its domain. It operates as a subsidiary of Magle AB, emphasizing its commitment to innovation and excellence in serving healthcare needs globally.

Products and Services

Magle Chemoswed offers a diverse range of products and services, designed to address various medical conditions and healthcare needs:

• Warfarin Sodium Products: These anticoagulants are used for multiple indications, providing essential treatment options in the management of blood clots and preventing stroke in patients with certain conditions.
• Melperone Hydrochloride: An antipsychotic agent, this medication is employed in the treatment of psychiatric disorders, showcasing Magle Chemoswed's contribution to mental health care.
• Isradipine: This calcium channel blocker is invaluable in the treatment of hypertension, evidencing the company's role in addressing cardiovascular diseases.
• Amantadine Sulfate: Used in treating central nervous system disorders, it underlines the company's involvement in neurology and the broader spectrum of CNS treatments.
• Benserazide Hydrochloride: In combination with L-Dopa, this medication is crucial for Parkinson's disease treatment, contributing significantly to neurodegenerative disease management.
• EmboCept S: A microsphere-based medical device for vascular occlusion in liver and lung tumors, it demonstrates Magle Chemoswed's innovative approach to cancer treatment.
• SmartGel: A non-allergenic hydrogel based on the company's microsphere technology, focused on advancing wound care through innovative solutions.
• SmartPAN: This medical device assists in the detection of pancreatic fluid leakage during surgical procedures, showcasing the firm's commitment to enhancing surgical outcomes.
• Upcoming Developments: Magle Chemoswed is also actively engaged in developing new solutions, including EmboCept M for benign prostatic hyperplasia, EmboCept L for uterine fibroids, SmartGel II for wound care, and SmartBone for bone growth in implant procedures, signaling its ongoing commitment to medical innovation and improving patient care.